GLP-1 Drug Biosimilar Market Top Companies Study - Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Biocon Biologics Ltd., Celltrion Inc.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global GLP-1 Drug Biosimilar Market Size, Share & Trends Analysis Report by Reference Biologic (Semaglutide Biosimilar, Liraglutide Biosimilar, Exenatide Biosimilar, Dulaglutide Biosimilar), by Formulation (Injectable Pen, Oral Tablet, Patch & Implant), by Distribution (Retail Pharmacy, Mail-Order & Specialty Pharmacy, Hospital & Clinic),- Market Outlook And Industry Analysis 2035"

GLP 1 Drug Biosimilar Market Size is valued at USD 3.40 Bn in 2025 and is predicted to reach USD 86.23 Bn by the year 2035 at a 40.0% CAGR during the forecast period for 2026 to 2035.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com//request-sample/3602

GLP-1 drug biosimilars are biological medicines developed to demonstrate a high degree of similarity to approved glucagon-like peptide-1 (GLP-1) receptor agonists used in the treatment of type 2 diabetes and obesity. These therapies help regulate blood glucose levels by stimulating insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety, thereby supporting effective glycemic control and weight management. As the global burden of diabetes and obesity continues to increase, demand for GLP-1-based therapies has grown significantly, creating substantial opportunities for the development of cost-effective biosimilar alternatives.

Rising awareness of obesity as a chronic disease, expanding access to biologic therapies, and increasing healthcare expenditure are encouraging pharmaceutical manufacturers to accelerate investment in GLP-1 biosimilar development.

The GLP-1 drug biosimilars market is entering a transformative phase, driven by the widespread clinical success of branded GLP-1 receptor agonists, including semaglutide and tirzepatide, in the management of type 2 diabetes and obesity. Strong clinical outcomes, rapidly growing patient demand, and the high cost of originator products have intensified the need for more affordable treatment options, positioning biosimilars as an important strategy for improving patient access while reducing healthcare costs.

The market is expected to undergo significant expansion as key intellectual property protections for leading GLP-1 therapies begin to expire over the coming years. Patent expirations anticipated from the latter half of the decade through the 2030s are expected to create favorable conditions for biosimilar market entry and increased competition. In response, pharmaceutical and biotechnology companies are actively advancing biosimilar candidates through analytical development, clinical evaluation, and regulatory pathways.

A growing development pipeline, combined with continuous improvements in biologics manufacturing technologies, process optimization, and regulatory experience, is expected to strengthen the competitive landscape. As clinical evidence supporting biosimilar safety, efficacy, and interchangeability continues to expand, GLP-1 drug biosimilars are anticipated to play an increasingly important role in broadening access to advanced metabolic therapies and supporting the long-term sustainability of healthcare systems worldwide.

Add our site to Google Preferred Sources for quality content: https://google.com/preferences/source?q=insightaceanalytic.com

List of Prominent Players in the GLP-1 Drug Biosimilar Market:
• Teva Pharmaceutical Industries Ltd.
• Sandoz Group AG
• Viatris Inc.
• Amgen Inc.
• Biocon Biologics Ltd.
• Celltrion Inc.
• Samsung Bioepis Co., Ltd.
• Dr. Reddy's Laboratories Ltd.
• Shanghai Henlius Biotech Inc.
• Lupin Limited
• Intas Pharmaceuticals Ltd.
• Alvotech
• Bio-Thera Solutions Ltd.
• Fresenius Kabi AG
• Coherus BioSciences Inc.
• Organon & Co.
• Dong-A ST Co., Ltd.
• Gan & Lee Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Zhejiang Huahai Pharmaceutical Co., Ltd.

Market Dynamics
Drivers
The global GLP-1 drug biosimilars market is expected to witness substantial growth, driven by the increasing prevalence of obesity and type 2 diabetes worldwide. The growing demand for therapies that effectively improve glycemic control while supporting long-term weight management has significantly expanded the use of GLP-1 receptor agonists, creating favorable conditions for the introduction of biosimilar alternatives. As healthcare systems seek cost-effective solutions to address the rising burden of chronic metabolic diseases, GLP-1 biosimilars are expected to play an increasingly important role in improving treatment accessibility and reducing overall healthcare expenditure.

A major factor supporting market expansion is the anticipated expiration of patents for several leading GLP-1 receptor agonists, which is expected to encourage greater competition and facilitate biosimilar market entry. In addition, increasing investments by pharmaceutical and biotechnology companies in biologics development, supportive regulatory initiatives that promote biosimilar adoption, and growing confidence among healthcare professionals regarding the safety and effectiveness of biosimilar medicines are further accelerating market growth. Expanding biologics manufacturing capabilities and rising awareness of affordable therapeutic alternatives are also expected to strengthen long-term market opportunities.

Challenges
Despite favorable growth prospects, the GLP-1 drug biosimilars market faces several development and commercialization challenges. Manufacturing biosimilar products involves highly complex biological production processes, extensive analytical characterization, and comprehensive clinical evaluation to demonstrate comparability with the reference product. Stringent regulatory requirements governing quality, safety, efficacy, and immunogenicity often increase development costs and extend product approval timelines.

Market adoption may also be constrained by strong physician and patient preference for established branded GLP-1 therapies, particularly in markets where originator products have demonstrated robust clinical outcomes and high brand recognition. In addition, competitive pricing pressures, manufacturing scale-up requirements, supply chain complexity, and market access challenges may affect the commercial success of biosimilar products. Addressing these factors through efficient manufacturing, competitive pricing strategies, and continued clinical evidence generation will be critical to supporting broader market penetration.

Regional Trends
North America accounted for a significant share of the global GLP-1 drug biosimilars market in 2025, supported by the high prevalence of obesity and type 2 diabetes, advanced healthcare infrastructure, and widespread adoption of biologic therapies. Strong healthcare expenditure, well-established reimbursement systems, and substantial investments in biosimilar research, development, and commercialization continue to strengthen the region's market position. In addition, supportive regulatory frameworks and increasing demand for cost-effective treatment alternatives are expected to encourage greater adoption of GLP-1 biosimilars over the coming years.

The Asia-Pacific region is projected to register the fastest growth during the forecast period. Market expansion is being driven by the rapidly growing patient population, improving access to healthcare services, increasing healthcare expenditure, and expanding biologics manufacturing capabilities across countries such as India, China, South Korea, and Japan. Government initiatives promoting affordable biologic medicines, ongoing investments in pharmaceutical manufacturing infrastructure, and the presence of experienced biosimilar developers are expected to create significant growth opportunities. As healthcare systems across the region continue to prioritize broader access to advanced diabetes and obesity treatments, Asia-Pacific is anticipated to emerge as one of the most dynamic markets for GLP-1 drug biosimilars.

Customize this Study according to your Requirements @ https://www.insightaceanalytic.com/customization/3602

Recent Developments:
• In June 2024: Teva launched the first generic GLP-1 product in the U.S. market through the introduction of an authorized generic version of Victoza (liraglutide), expanding access to GLP-1 therapies for patients with type 2 diabetes.

Segmentation of GLP-1 Drug Biosimilar Market-
By Reference Biologic -
• Semaglutide Biosimilar
• Liraglutide Biosimilar
• Exenatide Biosimilar
• Dulaglutide Biosimilar
By Formulation -
• Injectable Pen
• Oral Tablet
• Patch & Implant
By Distribution -
• Retail Pharmacy
• Mail-Order & Specialty Pharmacy
• Hospital & Clinic
By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Comprehensive Report Overview: https://www.insightaceanalytic.com/report/glp-1-drug-biosimilar-market/3602

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.